Lower baseline cerebrospinal fluid amyloid-β 42 is associated with amyloid-related imaging abnormalities during real-world lecanemab treatment.

Takahashi R, Kashibayashi T, Fujita J, Yoshida K, Hashiramoto A, Kowa H, Mizuta E.

Open source

DOI
10.1177/13872877261488874
Published
2026-09-15
Container
J Alzheimers Dis
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1177/13872877261488874,
  title = {Lower baseline cerebrospinal fluid amyloid-β 42 is associated with amyloid-related imaging abnormalities during real-world lecanemab treatment.},
  author = {Takahashi R and  Kashibayashi T and  Fujita J and  Yoshida K and  Hashiramoto A and  Kowa H and  Mizuta E.},
  year = {2026},
  journal = {J Alzheimers Dis},
  doi = {10.1177/13872877261488874},
  url = {https://doi.org/10.1177/13872877261488874}
}

RIS

TY  - JOUR
TI  - Lower baseline cerebrospinal fluid amyloid-β 42 is associated with amyloid-related imaging abnormalities during real-world lecanemab treatment.
AU  - Takahashi R
AU  -  Kashibayashi T
AU  -  Fujita J
AU  -  Yoshida K
AU  -  Hashiramoto A
AU  -  Kowa H
AU  -  Mizuta E.
PY  - 2026
JO  - J Alzheimers Dis
DO  - 10.1177/13872877261488874
UR  - https://doi.org/10.1177/13872877261488874
ER  - 

APA

R, T., T, K., J, F., K, Y., A, H., H, K., & E., M. (2026). Lower baseline cerebrospinal fluid amyloid-β 42 is associated with amyloid-related imaging abnormalities during real-world lecanemab treatment.. J Alzheimers Dis. https://doi.org/10.1177/13872877261488874

Source records